Skip to main content

Table 3 Clinical pathogical parameters and expression of CHD1L for prognosis of 102 patients with ovarian carcinoma by univariate survival analysis (log-rank test)

From: CHD1L Protein is overexpressed in human ovarian carcinomas and is a novel predictive biomarker for patients survival

Variable All cases Mean survival (months) Median survival (months) P value
Age at surgery     0.75
 ≤ 51a 54 74.4 NRb  
 > 51 48 92.9 NRb  
Histological type     
 Serous 72 78.4 NRb 0.55
 Mucinous 11 62.7 45  
 Othersc 19 88.4 NRb  
Histologicalgrade (Silveberg)     0.00
 G1 16 116.3 NRb  
 G2 61 87.5 NRb  
 G3 25 33.3 22  
FIGO stage     0.00
 I 19 57.2 NRb  
 II 10 59.1 NRb  
 III 58 34.1 NRb  
 IV 15 21.6 NRb  
Operation     0.00
Satisfactory cytoreductive operation 35 92.3 NRb  
Stage operation 32 121.4 NRb  
Unsatisfactory cytoreductive operation 25 47.6 22  
Chemical program     0.17
 TP 17 62.0 NRb  
Cyclophosphamide + Adriamycin + Carbo 41 83.5 66  
 Others 44 63.6 NRb  
Residual tumor     0.00
 None 32 121.2 NRb  
 <=2cm 35 92.3 NRb  
 >2cm 35 46.5 22  
CHD1L protein expression     0.03
 Negative 50 97.4 NRb  
 Positive 52 66.7 37  
  1. a Mean age.
  2. b Not reach.
  3. cEndometrioid, Clear cell and Undifferentiated types.